It is not known whether it is safe to consume alcohol with Lucentis. Please consult your doctor.
CONSULT YOUR DOCTOR
Lucentis may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
SAFE IF PRESCRIBED
Lucentis is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
UNSAFE
Lucentis may cause blurring of your vision for a short time just after its use. Do not drive until your vision is clear.
SAFE IF PRESCRIBED
Lucentis is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Lucentis may not be needed in these patients. Please consult your doctor.
SAFE IF PRESCRIBED
Lucentis is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Lucentis may not be needed in these patients. Please consult your doctor.
Medicine Overview of Lucentis 10mg/ml Injection
Introduction
Lucentis is used for the treatment of eye diseases which are caused by diabetes, macular degeneration, and macular swelling. It reduces the abnormal growth and leakage of blood vessels in the eye that can cause vision loss.
Lucentis is administered directly into the eyeball by an eye specialist. You should not self administer this medicine at home. The common side effects include eye pain, redness, blurred or decreased vision and eye discharge.
However, if you experience these side effects for a longer duration or any other symptoms which you think may be due to this medicine, please inform your doctor. It is not advised to drive after administration of this injection as it may cause blurring of vision.
Uses of Lucentis
Diabetic eye disease
Wet age-related macular degeneration
Macular oedema due to retinal vein occlusion
Side effects of Lucentis
Common
Conjunctival hemorrhage
Eye pain
Eye inflammation
Increased intraocular pressure
How to use Lucentis
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Lucentis works
Lucentis is an anti-angiogenic medication. It works by blocking a protein called vascular endothelial growth factor (VEGF). This stops the growth and leakage of abnormal blood vessels in the eye(s) that may cause vision loss.
What if you forget to take Lucentis?
If you miss a dose of Lucentis, please consult your doctor.
Quick Tips
Lucentis is used for the treatment of eye diseases caused by diabetes, macular degeneration and macular swelling.
It is administered directly into the eyeball by an eye specialist.
It may cause temporary visual disturbances. Don't drive or do anything that requires mental focus until you know how Lucentis affects you.
Inform your doctor if you experience increased eye pain and redness, blurred or decreased vision, or increased sensitivity to light.
Brief Description
Indication
Wet ARMD, Central retinal vein occlusion, Diabetic macular edema
Adult Dose
Intravitreal
Neovascular (wet) age-related macular degeneration
Adult: 0.5 mg (0.05 mL of 10 mg/mL) mthly into the affected eye as a single dose. Continue treatment until visual acuity is stable for 3 consecutive mth. Doses are given at intervals of at least 1 mth.
Macular oedema secondary to retinal vein occlusion
Adult: 0.5 mg mthly into the affected eye as a single dose for 6 months. Doses are given at intervals of at least 1 mth.
Diabetic Macular Edema, Diabetic Retinopathy with DME
0.3 mg (0.05 mL of 6 mg/mL) administer by intravitreal injection once a month (approximately every 28 days).
Contraindication
Active or suspected ocular or periocular infection, active severe intraocular inflammation, signs of irreversible ischaemic visual function loss in patients w/ retinal vein occlusion.
Mode of Action
Humanized monoclonal antibody to VEGF-A, inhibits VEGF-A-induced ocular neovascularization.
Precaution
Patient w/ risk factors for retinal pigment epithelial tears, history of stroke or transient ischaemic attack, uncontrolled HTN, previous intravitreal inj, active systemic infections, proliferative diabetic retinopathy, diabetic macular oedema due to type 1 DM. Discontinue treatment if rhegmatogenous retinal detachment or stage 3 or 4 macular hole develops. Diabetic patients w/ glycosylated Hb over 12%.
Lactation: Unknown if distributed in milk; use caution
May enhance the adverse/toxic effect of belimumab. Serious intraocular inflammation may occur when used adjunctively w/ verteporfin photodynamic therapy (PDT).
ফার্মেসীর জন্য পাইকারি দামে ঔষধ কিনতে রেজিস্টেশন করুন
The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.